IMCD has signed an agreement to acquire Daoqin, a Chinese distributor of functional nutrition, food, and nutraceutical ingredients.
Daoqin, with ~$17.08 million revenue in 2023, will strengthen IMCD’s presence in China’s life sciences market.
Both companies highlight strong synergies and technical expertise, with the deal expected to close in Q2 2025.
IMCD has signed an agreement to acquire Daoqin, a Chinese distributor of functional nutrition, food, and nutraceutical ingredients.
Daoqin, with ~$17.08 million revenue in 2023, will strengthen IMCD’s presence in China’s life sciences market.
Both companies highlight strong synergies and technical expertise, with the deal expected to close in Q2 2025.